Blair William & Co. IL Sells 4,778 Shares of Insulet Co. (NASDAQ:PODD)

Blair William & Co. IL lessened its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 183,285 shares of the medical instruments supplier's stock after selling 4,778 shares during the quarter. Blair William & Co. IL owned about 0.26% of Insulet worth $47,850,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in PODD. SBI Securities Co. Ltd. bought a new position in Insulet in the 4th quarter worth $36,000. SRS Capital Advisors Inc. grew its position in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares during the last quarter. Friedenthal Financial bought a new position in shares of Insulet in the fourth quarter worth about $57,000. TD Private Client Wealth LLC lifted its position in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after purchasing an additional 56 shares during the last quarter. Finally, Assetmark Inc. boosted its stake in Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares during the period.

Insulet Price Performance

Insulet stock traded up $0.97 during mid-day trading on Tuesday, hitting $263.58. 129,686 shares of the company were exchanged, compared to its average volume of 704,888. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The business has a fifty day moving average of $271.42 and a 200 day moving average of $259.20. The company has a market capitalization of $18.51 billion, a PE ratio of 45.52, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Remove Ads

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, sell-side analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at $888,525. This represents a 36.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on PODD shares. Stifel Nicolaus lifted their price target on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Citigroup upped their target price on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. TD Cowen increased their price target on shares of Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a report on Friday, January 3rd. Wells Fargo & Company boosted their price objective on shares of Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Finally, StockNews.com cut shares of Insulet from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.